Dublin-listed Open Orphan to test Covid-19 drug through London subsidiary

As many as 100 potential Covid-19 candidate vaccines are now under development by biotech and research teams around the world

A team at  Oxford University in Britain has dosed the first volunteers in a trial of its Covid-19 vaccine “ChAdOx1 nCoV-19” .  Photograph: iStock

A team at Oxford University in Britain has dosed the first volunteers in a trial of its Covid-19 vaccine “ChAdOx1 nCoV-19” . Photograph: iStock

Dublin-listed pharma services company Open Orphan has begun testing an anti-viral treatment for Covid-19 through its London-based subsidiary Hvivo.

The testing is being carried out on behalf of Nearmedic International, a specialist pharmaceutical, biotechnological and medical company headquartered in Moscow.

Please subscribe or sign in to continue reading.
only €1 first month

Insightful opinion is just a away.